Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Cytomegalovirus (CMV) is one of the most important infectious causes of morbidity and mortality in children undergoing haematopoietic stem cell transplant (HSCT). However, the evidence for preventing and treating CMV disease in children in this context remains limited. We sought to review the current available evidence regarding the prevention and management of CMV infection and disease in children with HSCT and propose future research areas which could better inform evidence-based management.

More information Original publication

DOI

10.1002/rmv.70120

Type

Journal article

Publication Date

2026-03-01T00:00:00+00:00

Volume

36

Keywords

CMV, children, prevention, transplant, treatment, Humans, Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation, Child, Antiviral Agents, Cytomegalovirus